SDG
Developer of bio-nanotechnology delivery systems focused on nanoscale bilayer phospholipid carriers (20–50 nm) for oral protein delivery, cell-receptor targeting, and consumer-product actives. Technologies have been evaluated in human clinical studies and the company supports cGMP manufacturing, stability testing, and technology licensing/partnerships.
Industries
Nr. of Employees
small (1-50)
SDG
Cleveland, Ohio, United States, North America
Products
Hepatic-targeted vesicle formulations for oral protein delivery
Vesicle-based formulations designed to deliver protein therapeutics to the liver via oral administration for metabolic disease indications.
Bio-nano liposome carriers for therapeutic, diagnostic, and consumer actives
Nanoscale bilayer carriers compatible with proteins, small molecules, imaging agents, nutraceuticals, fragrances, sunscreens, and hair/skin actives.
Hepatic-targeted vesicle formulations for oral protein delivery
Vesicle-based formulations designed to deliver protein therapeutics to the liver via oral administration for metabolic disease indications.
Bio-nano liposome carriers for therapeutic, diagnostic, and consumer actives
Nanoscale bilayer carriers compatible with proteins, small molecules, imaging agents, nutraceuticals, fragrances, sunscreens, and hair/skin actives.
Services
Technology licensing and joint development
Licensing of bio-nano delivery technologies and collaborative development agreements with industry partners and contract collaborators.
cGMP manufacturing of nanocarriers
Commercial-scale manufacturing of nanoscale bilayer carrier systems under current Good Manufacturing Practices.
Technology licensing and joint development
Licensing of bio-nano delivery technologies and collaborative development agreements with industry partners and contract collaborators.
cGMP manufacturing of nanocarriers
Commercial-scale manufacturing of nanoscale bilayer carrier systems under current Good Manufacturing Practices.
Expertise Areas
- Oral protein delivery
- Nanoparticle/bilayer vesicle formulation
- Cell-receptor targeted drug delivery
- Preclinical and clinical study execution
Key Technologies
- Bilayer phospholipid vesicle carriers (20–50 nm)
- Cell-receptor targeting ligands
- Immune-masking agents (non-PEG)
- Oral protein formulation